Combining Vela’s long-standing expertise in the characterization of biosimilars with Evercyte’s know-how to immortalize relevant primary target cells, the partnership will provide product-tailored bioassays. A VEGF-responsive cell line (HUVEC) has already been established for potency testing of bevacizumab (Avastin) biosimilars.
“In terms of regulatory compliance, stable cell lines are much more reliable than primary cells. We are pleased to bring bioassays based on this distinct advantage to our customers in the global biopharmaceutical industry”, said Dr. Andreas Nechansky, co-founder and COO of VelaLabs. “Making immortalized cell lines available for GMP testing complements the broad analytical method portfolio we have developed to serve the needs of manufacturers of biopharmaceuticals and biosimilars worldwide”.
“The need of product relevant cell lines that can be standardized is ever increasing in view of restrictions on the use of laboratory animal as well as the increased demand for analyzing the biological activity of biosimilars and biopharmaceuticals”, said Dr. Johannes Grillari, co-founder and CSO of Evercyte. “Therefore, our cooperation aims to introduce Evercyte’s cell lines into the GMP environment and to establish novel, relevant cell lines, including innovative reporter cell lines, for specific biopharmaceuticals, again for use under GMP conditions”.